Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech and CGI in drug development deal
Under the terms of the multi-year agreement, Genentech makes an upfront payment to CGI of $25 million. Genentech obtains an exclusive license to develop and market small molecules
Under the terms of the multi-year agreement, Genentech makes an upfront payment to CGI of $25 million. Genentech obtains an exclusive license to develop and market small molecules
The study will evaluate the efficacy and safety of Zevalin in patients with diffuse large-B-cell lymphoma (DLBCL) the most common type of aggressive non-Hodgkin's lymphoma. The primary endpoint
Lodotra is a new, modified-release tablet that has been developed in partnership with Nitec Pharma to optimize the efficacy of orally administered low-dose prednisone in rheumatoid arthritis. Lodotra
Under the expanded agreement, UCB has made an upfront payment and will make milestone payments to Jazz Pharmaceuticals. If the product is approved, UCB obtains the right to
The study compared these results to patients taking an alternative treatment for MS called interferon beta. Only 30% of patients taking interferon beta remained on the treatment. The
Ozarelix is used in the treatment of Benign Prostatic Hypertrophy (BPH), an enlargement of the prostate gland. The trial was conducted in Europe in collaboration with Spectrum’s partner
This phase I dose escalation study is intended to define the dose limiting toxicities and maximum tolerated dose of ADH-1 in three separate studies with the chemotherapy treatments
Peripheral T-cell lymphomas, or PTCLs, are an uncommon group of blood cancers that account for approximately 10% to 15% of all cases of non-Hodgkin’s lymphoma, or about 6,700
Osteoarthritis (OA) is the most common form of arthritis and is caused by the breakdown and loss of the cartilage of one or more joints. Approval of this
The results were from stage one of a two-stage phase II trial of ispinesib administered as monotherapy in the treatment head and neck cancer. This two-stage clinical trial